Latest Drug Mechanism Of Action News

Page 1 of 1

Race Oncology Unveils Dual Cardioprotective and Anticancer Promise of RC220 at ESMO 2025

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

Ada Torres

20 Oct 2025

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026